The Biotin Enzyme Also Breaks Down Opioid Peptides — An Unexpected Dual Function
Human serum biotinidase degrades enkephalins and short dynorphin with efficiency comparable to its biotin substrate — revealing an unexpected link between vitamin metabolism and opioid peptide regulation.
Quick Facts
What This Study Found
Human serum biotinidase hydrolyzes enkephalins and dynorphin A (<10-mer) with kcat/Km values similar to its biotin substrate biocytin.
Key Numbers
How They Did This
Purified human serum biotinidase was tested against various peptide substrates. Kinetic parameters (kcat, Km) were determined. Inhibition studies used various antibiotic inhibitors.
Why This Research Matters
This reveals a previously unknown way the body controls opioid peptide levels in the blood. Biotinidase deficiency, a known genetic condition, might affect opioid peptide metabolism.
The Bigger Picture
Biotinidase deficiency is a known genetic condition treated with biotin supplementation. If this enzyme also controls opioid peptide levels, patients with biotinidase deficiency may have altered opioid signaling — potentially affecting pain sensitivity or mood.
What This Study Doesn't Tell Us
In vitro study using purified enzyme. Conditions differ from the complex blood environment. Clinical significance of this activity is unknown.
Questions This Raises
- ?Do biotinidase-deficient patients have altered opioid peptide levels?
- ?Could biotinidase contribute to pain sensitivity differences between individuals?
Trust & Context
- Key Stat:
- Equal efficiency for biotin and opioids Biotinidase degrades enkephalins with kcat/Km values similar to its canonical biotin substrate
- Evidence Grade:
- Preliminary in-vitro enzyme study. Demonstrates the dual activity but clinical significance is unknown.
- Study Age:
- Published in 1991. The broader implications for biotinidase deficiency patients remain understudied.
- Original Title:
- Enkephalin hydrolysis by human serum biotinidase.
- Published In:
- Biochimica et biophysica acta, 1074(3), 433-8 (1991)
- Authors:
- Oizumi, J, Hayakawa, K
- Database ID:
- RPEP-00203
Evidence Hierarchy
Frequently Asked Questions
What is biotinidase?
An enzyme that releases biotin (vitamin B7) from proteins during digestion and recycling. Biotinidase deficiency is a genetic condition that can cause neurological problems if untreated.
Could biotinidase deficiency affect pain sensitivity?
Theoretically yes. If biotinidase normally degrades opioid peptides in the blood, its absence could lead to higher circulating opioid peptide levels — potentially affecting pain perception, though this hasn't been clinically tested.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00203APA
Oizumi, J; Hayakawa, K. (1991). Enkephalin hydrolysis by human serum biotinidase.. Biochimica et biophysica acta, 1074(3), 433-8.
MLA
Oizumi, J, et al. "Enkephalin hydrolysis by human serum biotinidase.." Biochimica et biophysica acta, 1991.
RethinkPeptides
RethinkPeptides Research Database. "Enkephalin hydrolysis by human serum biotinidase." RPEP-00203. Retrieved from https://rethinkpeptides.com/research/oizumi-1991-enkephalin-hydrolysis-by-human
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.